CYTOKINETICS INC (CYTK)

Company Profile

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 423 full-time employees. The company went IPO on 2004-04-29. The firm specializes in muscle biology and the mechanics of muscle performance. The company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

Company Info

CYTOKINETICS INC

350 Oyster Point Boulevard

South San Francisco CALIFORNIA 94080

P: 16506243000

CEO: Robert I. Blum

Employees: 423

Website: https://cytokinetics.com/